Search Prime Grants

R01HL155559

Project Grant

Overview

Grant Description
A Mechanistic Trial of Dietary Sodium Reduction on Vascular Structure and Function in African Americans - Project Summary

High dietary sodium intake increases the risk of cardiovascular disease (CVD) independent of established risk factors, including blood pressure (BP). Non-BP mediated mechanisms underlying the increased risk of CVD associated with dietary sodium intake are not well understood, but observational studies suggest direct target organ damage in the heart and vasculature might play an important role.

Little evidence exists from randomized controlled trials (RCTs) on target organ effects of dietary sodium reduction, and the National Academy of Medicine has recommended future research to "test the effects of different sodium intake levels on endothelial and vascular function" in order to "better characterize the relationship between sodium intake and chronic disease". Furthermore, no RCTs have been powered to test the effect of dietary sodium reduction on subclinical cardiovascular structure and function in African Americans, who are more sensitive to dietary sodium intake and at higher risk for CVD.

The overall objective of the proposed mechanistic trial is to test the effect of dietary sodium reduction on cardiac and vascular structure and function. Specifically, the proposed trial will test whether dietary sodium reduction (targeting a dietary sodium intake of <2,300 mg/day) will improve left ventricular mass index (LVMI), left ventricular global longitudinal strain (LVGLS), carotid-femoral pulse wave velocity (CFPWV), and flow-mediated dilation (FMD) compared to usual intake. Additionally, we will test whether this effect is independent from BP reduction.

We will recruit 240 African Americans with elevated BP or hypertension from the greater New Orleans area and randomly assign them to a dietitian-led behavioral intervention aimed at decreasing dietary sodium intake to <2,300 mg/day for 12 months or to a usual diet. Study outcomes, including cardiac magnetic resonance imaging (CMR)-determined LVMI and LVGLS, CFPWV, and FMD, will be measured at baseline, 6-month, and 12-month clinic visits using standardized protocols with stringent quality control. These outcomes are validated biomarkers for target organ damage and predict the risk of clinical CVD events.

In primary analyses, the effect of sodium reduction on each subclinical CVD endpoint will be compared between the sodium reduction and usual diet groups according to the intention-to-treat principle without adjusting for covariates. In secondary analyses, changes in ambulatory and clinical BP will be adjusted to assess the BP-independent effect of dietary sodium reduction on each subclinical CVD endpoint.

The proposed trial has 85% statistical power to detect a clinically significant difference in changes of the four co-primary outcomes (10 g/m2 in LVMI, 1.3% in LVGLS, 0.9 m/s in CFPWV, and 1.1% in FMD) over 12 months between the two groups at a 2-sided significance level of 0.0125 (0.05/4). This study is the first RCT to test the effect of dietary sodium reduction on subclinical CVD endpoints in African Americans.

Findings from this trial will fill the knowledge gap of the underlying mechanisms of dietary sodium intake on CVD risk and provide further evidence on sodium reduction for CVD prevention.
Funding Goals
NOT APPLICABLE
Place of Performance
New Orleans, Louisiana 70112 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the total obligations have increased 393% from $686,831 to $3,388,859.
The Administrators Of Tulane Educational Fund was awarded Dietary Sodium Reduction Trial: Impact on Vascular Health in African Americans Project Grant R01HL155559 worth $3,388,859 from National Heart Lung and Blood Institute in January 2022 with work to be completed primarily in New Orleans Louisiana United States. The grant has a duration of 5 years and was awarded through assistance program 93.837 Cardiovascular Diseases Research. The Project Grant was awarded through grant opportunity Research Project Grant (Parent R01 Clinical Trial Required).

Status
(Ongoing)

Last Modified 9/21/26

Period of Performance
1/17/22
Start Date
12/31/26
End Date
98.0% Complete

Funding Split
$3.4M
Federal Obligation
$0.0
Non-Federal Obligation
$3.4M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R01HL155559

Subgrant Awards

Disclosed subgrants for R01HL155559

Transaction History

Modifications to R01HL155559

Additional Detail

Award ID FAIN
R01HL155559
SAI Number
R01HL155559-285769947
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Funding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Awardee UEI
XNY5ULPU8EN6
Awardee CAGE
1BHK1
Performance District
LA-02
Senators
Bill Cassidy
John Kennedy

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Heart, Lung, and Blood Institute, National Institutes of Health, Health and Human Services (075-0872) Health research and training Grants, subsidies, and contributions (41.0) $1,371,732 100%
Modified: 9/21/26